Koçer, AbdulkadirDikici, SüberAtakay, SelçukOkuyucu, Şefika2020-04-302020-04-3020080017-87481526-4610https://doi.org/10.1111/j.1526-4610.2007.01008.xhttps://hdl.handle.net/20.500.12684/4521Kocer, Abdulkadir/0000-0003-2866-555XWOS: 000257483200008PubMed: 18179568Objective.-Topiramate (TPM) therapies for epilepsy or migraine are long-time therapies with unknown mechanisms and special side effects. TPM influences cholesterol (TC) and lipoprotein serum levels. In addition, TPM may cause uric acid (UA) stone formation. Material and Methods.-Serum UA, TC, and triglyceride (TG) levels were measured in 53 migraine patients receiving TPM and in 44 age- and sex-matched controls. Compared with controls, patients on TPM showed significantly higher UA and nonsignificantly higher TC and TG values. We recorded pre- and posttreatment levels of UA, TC, and TG levels in 23 patients. Results.-We found increased serum levels of UA with TPM use (P < .01). There was a significant and positive correlation between serum UA levels and male gender (P < .01).The changes in serum UA levels before and after TPM treatment differed significantly (P < .01). Conclusion.-Our results suggest a need for monitoring serum UA levels in patients receiving TPM. We should perhaps prescribe a low-UA diet and advice to drink much more water in these patients.en10.1111/j.1526-4610.2007.01008.xinfo:eu-repo/semantics/closedAccessuric acidcholesteroltriglyceridetopiramatemigraineantiepileptic treatmentArticle48710561060WOS:000257483200008Q1Q2